← Back to headlines
Immunic Secures $400 Million Funding for Commercial Development
Biopharmaceutical company Immunic has successfully secured $400 million in funding to advance its commercial-stage development projects.
16 Feb, 10:48 — 16 Feb, 10:48
Sources
Showing 1 of 1 sources
